anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain an incensing composition with hardly any smoke in burning by coating or adsorbing a coloring matter, an incense or a perfume on a base such as silica gel, perlite or volcanic ash or further mixing active carbon therewith. CONSTITUTION:The objective incensing composition is obtained by coating or adsorbing a coloring matter, an incense or a perfume on one or a mixture of two or more of silica gel, perlite, volcanic ash, activated clay, activated alumina, coal ash and zeolite as a base and mixing preferably &gt;=10wt.% resultant coated or adsorbed coloring matter, etc., therein. This incensing composition emits a small amount of smoke in burning and is good in fragrant odor-retaining properties. Active carbon may be blended in the main raw materials. The incensing substance is used especially for burning an incense. The amount of smoke and a fragrant odor produced by burning the incense, etc., by this incensing substance can moderately be regulated. This composition is capable of not only reducing fouling, an unpleasant odor and damage to the respiratory system of a human body due to a large amount of the smoke but also preventing disadvantages of sticking to wall surfaces and furniture in the room and fouling them. Since the colorability is excellent, this composition is practical.
FIELD: medicine, surgery. SUBSTANCE: one should carry out radical surgical sanitation of purulent-septic focus followed by its adequate draining. One should compensate the volume of circulating blood and general heparinization. One should carry out lymphatic drainage of tissues due to intravenous injection of rheopolyglukin. Extracorporal addition of donor&#39;s xenospleen is performed along veno-venous contour. Both patient&#39;s subclavicular veins are catheterized. Autoblood is directed into xenosplenic artery. Patient&#39;s blood is passed through xenosplenic vascular system in constant magnetic field at induction of 50 mTl for 55-60 min at 30-45 ml/min rate at total volume of 1600 ml, not less. Blood&#39;s output is conducted out of xenospleen through its vein. Laser irradiation of blood is carried out with low-intensity laser radiation for 55-60 min, at 0.63 mcm wave length, 1.8-2.0 mW power. When autoblood sampling is stopped, spleendeposited blood is removed with 400.0 ml ozonized Ringer-Locke&#39;s solution at 2-3 mg/l ozone concentration. After xenospleen is removed, one should introduce 0.03%- sodium hypochlorite solution at 30-40 drops/min rate and 200.0 ml volume. The present innovation enables to prevent entrance of toxins out of infection focus and remove already entered toxins from circulatory system. EFFECT: higher efficiency of surgical treatment. 4 cl, 2 ex, 1 tbl
Air freshener consists of crystals of starting material (pref. heliotropin, vanillin, musk ketone, musk seed or musk xylene or their mixts) impregnated with liq. perfumes. Impregnation is carried out with heating. A pref. process comprises melting 8.5 kg of starting material and heating it to 80 degrees C. 1.5 kg of liquid perfume concentrate is added and the mixt. stirred 3 mins while maintaining the same temp. It is then poured into a vessel in which if forms a layer is not &gt;5 cm high. Ultrasonic waves are passed through for 5 mins. to homogenise it. It is allowed to cool while stirring, to give a solid sheet which is broken up to give irregular particles. The air freshener may be placed in drawers, cupboards etc. It operates under ambient temp. conditions.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a clinical trial data generation device capable of correctly inputting clinical trial data for investigating the influence of dosing.  &lt;P&gt;SOLUTION: A CPU 11 transmits time information corresponding to the number of days after the starting day of dosing to an electronic clinical card system 30. In a database that the electronic clinical card system 30 has, observed data by patients are itemized and stored while making correspondence to the time information. For an item which is not included in the database, the CPU 11 transmits image information to a terminal 20 to expedite an input of data corresponding to the item and makes a person in charge of the terminal 20 input it. The CPU 11 generates the clinical trial data by using data supplied from the database and the terminal 20.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
A system and method tracks medical articles and containers by providing a robust electromagnetic (EM) field within an enclosure in which the articles and containers are stored. Respective data carriers, such as RFID tags, attached to each article or container respond to the electromagnetic field by transmitting unique identification data. A data base associates the data carrier identification data with data about the medical articles or containers including type of medicine, size of the dose, and expiration date. A processor notifies a pharmacy when a medical article is received and when removed. The processor also notifies the finance department regarding patient medical articles and administration to update the patient&#39;s Medication Administration Record. The processor also provides inventory level counts and expiration dates.
The present invention discloses medicine for treating gastropathy, which is Chinese patent medicine with raw material composed of auriculate swallowwort roots, Kujinpe, aucklandia roots, haws, asarum herbs, licorice roots, cinnamon, Chicken&#39;s Gizzard membrane and medicated leaven. The Chinese patent medicine is prepared according to conventional preparation technology. The medicine is the medicine prepared by the medicine theory of the nationality of miao. Chinese herbal medicine which is common in local areas is used as raw material and has low cost. The medicine has the functions of warming middle-jiao, enlivening spleens, lowering the adverse flow of spleens, nourishing stomachs, promoting qi circulation and relieving pain and good therapeutic effects. The medicine has the characteristics of simple preparation, low cost and good therapeutic effect. The medicine can be used for curing patients with the symptoms of deficiency of spleens and stomachs, abdominal cold pain, dyspeptic abdominal distention, fullness in chests and hypochondrium, poor appetite, peptic ulcer disease, chronic gastritis, pancreatitis and cholecystitis.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a sheet substrate for a wet sheet, which has an excellent feeling and in which a liquid slightly moves even if a plurality of substrates impregnated with the liquid are preserved in a laminated state.  &lt;P&gt;SOLUTION: The sheet substrate for a wet sheet is impregnated with a liquid to give a wet sheet. The sheet substrate comprises a fiber sheet containing ≥55 wt.% of one or more kinds of hydrophilic fibers. The fiber diameter of the fiber is 0.2-5.5 dtex and a distance between fibers constituting the sheet is 10-35 μm. The sheet substrate is preferably composed of a spun lace nonwoven fabric.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
An extract is derived from Pueraria candollei var. mirifica A Shaw. &amp; Suvat. for topical and internal use in treating a subject. The extract is obtained by a sequential extraction process using a sequence of different solvents or mixtures of solvents in varying ratios and thereafter combining the liquid extracts. The liquid extract is then evaporated to dryness to obtain the extract. The extract is used in a topical composition that when applied to the skin reduces wrinkles without eye irritation.
The device of the present invention includes a modular, implantable catheterization port that is composed of a body portion, an interior port and an exterior port. The interior and exterior ports are selectively attachable to the body portion such that the device can be assembled by a clinician at the skin entry site without compromising the position of other portions of the device within and outside of the patient. The device further includes a first skirt and a second skirt that surround the exterior port at its junction with the body portion. Both skirts are designed to gradually affix themselves into the surrounding tissues of the patient&#39;s body during the initial phase of healing. The first skirt is composed of a bio-absorbable material such that in subsequent phases of healing its connection to the surrounding tissues diminishes, leaving the second skirt to maintain a mature, secure, and permanent connection to the tissues. The bio-absorbable material can be selected prior to assembly in order to ensure that the first skirt is fully absorbed at the conclusion of the procedure, thus permitting an easy and less-invasive removal of the device from the patient.
A smart registration system, a machine and a method are provided. The smart registration system includes a cloud database and a smart registration machine. The cloud database includes a user data storage module and a disease data storage module. The user data storage module stores a plurality of user basic data and a plurality of user facial images. The disease data storage module stores multiple disease names and multiple disease symptoms. The smart registration machine is used to scan the face of a user to generate an image of the user&#39;s face, and to receive the verbal description of the user&#39;s illness to generate a voice signal, and then use the analysis and judgment module to compare a current user&#39;s face Partial images, a current user’s basic information, and at least one recommended registration department, so as to register to the online registration system based on the recommended registration department and the current user’s basic information.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new active oxygen scavenger, and active oxygen-scavenging skin care preparation excellent in active oxygen scavenging effect.  &lt;P&gt;SOLUTION: The active oxygen scavenger includes a white sandalwood extract as the active agent. The active oxygen-scavenging external preparation for the skin and the cosmetic include the scavenger. The white sandalwood extract is obtained by the extraction with an aqueous medium. The active oxygen scavenger is highly safe to the skin, and useful for an effective ingredient and the like for a skin care preparation.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a plaster for treatment with endermic medication easily and stably sticking a powdery medicine on a pressure sensitive adhesive sheet without spattering and to provide a method for producing the same.  &lt;P&gt;SOLUTION: The invention relates to the plaster comprising a first releasing paper 1 having a plurality of holes 11 formed in a row, a plurality of base pieces 2 formed as sufficiently large in size compared to the holes 11 and has a pressure sensitive adhesive face 21 on one side, and a second releasing paper 5 to be pasted on the back face 12 of the first release paper 1. Each of the pressure sensitive adhesive face 21 of the plurality of base pieces 2 is applied as to seal the hole 11 on the surface 13 of the first releasing paper 1. The powdery endermic medicine 3 is applied to the pressure sensitive adhesive parts of the base pieces 2 being exposed from the holes 11 on the back face 12 of the first releasing paper 1. The second release paper 5 is applied to the back face 13 of the first release paper 1 as to seal the part being exposed from the hole part 11 and applied with the powdery endermic medicine 3.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a transparent base material having a transparent external appearance, good brightness (gloss), hardness, usability, texture (smooth, well speadable, and unsticky), color effect, gloss effect, moisturizing effect, and good durability of these effects.  &lt;P&gt;SOLUTION: The gelling agent composition includes an N-acyl-L-acidic amino acid dialkylamide and a sugar fatty acid ester which is liquid at ordinary temperatures and/or a polyol fatty acid ester. In preparing the transparent base, the gelling agent composition can be dissolved at a low temperature of not higher than 100°C to enable the preparation of the transparent base excellent in stability without causing syneresis with time or in a high temperature state, a waste liquid, and sweating, and excellent in brightness (gloss), a feeling of use, and a feeling of finishing. The obtained transparent base excels in external appearance such as transparency, brightness (gloss), and color developability and can be suitably used in various applications such as a texture, a feeling of use, a moisturizing effect, coloring intensity and durability thereof. The transparent base can be used in a lip cream, a lip gloss agent, a lip color gloss agent, and the like.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
206,487. Hoffmann-La Roche &amp; Co. Akt.-Ges., F. Nov. 1, 1922, [Convention date]. Emulsions, making; hypodermic injections; medicines for internal use.-Emulsions in oils of bismuth salts of higher fatty acids, suitable for hypodermic. intravenous, intramuscular or other parenteral injections, are prepared by dissolving the bismuth salts in a volatile organic solvent, mixing the solution with the oil and removing the solvent by evaporation. Suitable oils are natural oils, synthetic fatty acid esters and mineral oils. In examples, bismuth oleate is emulsified in olive oil, almond oil or paraffin oil, using ether as the solvent; the bismuth salt of tartaric acid di-iodide in olive oil using ether, benzene or petroleumether as solvent; and the bismuth salt of linolic acid in almond oil with ether as solvent. In all cases the solvent is evaporated first at atmospheric pressure and finally in vacuo.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a bathing agent composition which can effectively use a situation resulting in a skin-beautifying effect under the conditions of a thermal effect and a moisture effect in bath water.  &lt;P&gt;SOLUTION: This bathing agent composition is characterized by containing coenzyme Q10. The bathing agent composition exhibits an extremely high skin roughness-improving effect, a moisture-retaining effect, and a skin-beautifying effect. The coenzyme Q10 has been known to be effective to allergic symptoms such as pollinosis, and can easily be applied to the whole body, when used as the bathing agent. Since the coenzyme Q10 has extremely low solubility in water, it can be expected that the coenzyme Q10 is selectively adsorbed to the skin during a bathing and effectively acts on the skin.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
NEW MATERIAL:The aniline derivative of formula I (R&lt;1&gt; is CH3 or C1211H5; R&lt;2&gt; is H or benzyl) and its acid addition salt. EXAMPLE:2-Methyl-N-(3-piperidinopropyl)aniline. USE:A muscle relaxant. Dose: 100-1,000mg of the active component daily for adult. PROCESS:The compound of formula I can be prepared by reacting the aniline derivative of formula II with the piperidine derivative of formula III (X is halogen, acyloxy, mesyloxy or tosyloxy) in the presence or absence of a solvent, preferably in the presence of a base such as NaOH, etc. at a temperature between 0 deg.C and the boiling point of the solvent.
PURPOSE:To obtain a new compound having a capillary active effect, useful especially as a base material for a skin care cosmetic, excellent in extension on the skin or affinity to the skin and capable of providing a cosmetic excellent in feeling in use. CONSTITUTION:This compound is expressed by formula I [R is an (un)saturated straight- or branched-chain 1 to 24C hydrocarbon], e.g. 3-O-octyl-1,2- Oisopropylidene-D-glucofuranose. The compound is obtained by reacting 1,2;5,6-di- O-isopropylidene-D-glucofuranose with an etherifying agent (preferably an alkyl chloride, etc.) in the presence of an alkaline substance (preferably NaOH, etc.) and a catalyst composed of a quaternary onium salt (preferably a quaternary ammonium salt such as tetrabutylammonium bromide) and subsequently hydrolyzing the resultant 3-0-alkyl-1,2;5,6-di-O-isopropylidene-D-glucofuranose of formula II at &lt;=450 deg.C. In addition, hydrolysis is conducted recommendably in the presence of an acid in a 1 to 4C alcohol such as methanol.
PURPOSE:To detect the anti L-alpha2M antibody in a patient&#39;s serum and to diagnose exactly the IgA kidney disease by using a carrier carrying the low molecule-alpha2-macroglobulin (L-alpha2M) which is the antigen to cause the IgA kidney disease, an enzyme labeled anti-IgA and an enzyme coloring substrate. CONSTITUTION:The alpha2-macroglobulin obtd. from the placenta, etc. is treated at 2-4pH to prepare L-alpha2M. The reagent 1 formed by binding such L-alpha2M with a carrier consisting of a synthetic resin tube, etc. of polystyrene, etc., an IgA antibody labeled by peroxidase, beta-D galactosidase, etc. and a substrate which colors by enzyme reaction are made into a kit. The dilute liquid of a specimen (serum) is added to the tube of the reagent 1 and after incubation, the reagent is cleaned and the enzyme labeled antibody is added thereto and the reagent is further incubated and cleaned. The coloring substrate is added to such reagent 1 and the optical density is measured with the specific wavelength of the color formed by said substrate. The optical density is higher with the IgA kidney disease than the serum of the other kidney patient or the normal serum of the control and therefore the exact diagnosis is made possible.
An antibiotic resin adsorbate comprises the reaction product of bacitracin and a particulate cross-linked cation-exchange resin consisting of a sulphonated styrene/divinyl benzene copolymer, or a monovalent cation salt thereof, e.g. a sodium, potassium or ammonium salt.  In examples bacitracin sulphate is reacted with a sodium salt of the resin.  The adsorbate finds application as a feed supplement in swine and poultry feeds.ALSO:In a process for the isolation and purification of bacitracin from aqueous solution, the pH of the solution is adjusted to from 3 to 7 (e.g. with sulphuric acid) and the solution is then contacted with a salt of a sulphonated copolymer of styrene with divinyl benzene, to cause adsorption of the bacitracin on the copolymer.  Elution of the bacitracin from the adsorbate obtained, may be effected with an aqueous base having a pH of 7.5 to 8.5, e.g. with 2% sodium carbonate solution.  In examples bacitracin sulphate is contacted with a sodium salt of the sulphonated copolymer.ALSO:An antibiotic feed supplement comprises a feed acceptable diluent together with an adsorbate of bacitracin on a salt of a sulphonated styrene/divinyl benzene copolymer, said adsorbate being present in from 5 to 50 grams of bacitracin activity per pound of supplement.  The adsorbates may be used in conjunction with other antibiotic or therapeutic agents such as penicillin, oxytetracycline, chlortetracyline, tetracycline, phenyl arsonic acid or sulphaquinoxaline and may be blended with grains, fish meal, bone meal, soybean meal, limestone, vitamins and amino acid ingredients. In examples specified feed ingredients are corn, soybean meal, corn gluten meal, alfalfa meal, animal fat, fish meal, corn solubles, whey, brewers&#39; yeast, iodized salt, calcium carbonate, calcium phosphate, Delamix, methionine, Vitamins A, B12 and D3, riboflavin, calcium pantothenate, niacin, choline chloride, diphenylphenylenediamine, skim milk, sucrose, mineral mix and saccharin.  The feed supplements are of particular use for swine and poultry feeds.
The present disclosure provides platinum-containing conjugates that selectively target and kill tumor/cancer cells. The conjugates contain a moiety that selectively targets COX-2, which is overexpressed by a broad range of tumor/cancer cells. The present disclosure provides conjugates that selectively target and kill tumor/cancer cells. The expression of cyclooxygenase II (COX-2) is upregulated in many benign and malignant tumor/cancer cells. In some embodiments, the conjugates comprise a COX-2-targeting moiety and a platinumcontaining antitumor agent. The term &#34;antitumor agents&#34; includes antitumor agents and anticancer agents. In some embodiments, the COX-2-targeting moiety comprises a non-steroidal anti-inflammatory drug (NSAID). In certain embodiments, the COX-2-targeting moiety comprises a COX-2-selective inhibitor.
1430958 6,14-Endo-ethe(a)ne-tetrahydro nororipavines and thebanes BOEHRINGER INGELHEIM GmbH 18 June 1973 [19 June 1972] 28870/73 Heading C2C Novel compounds I in which R is hydrogen, methyl or acetyl, R 1  is hydrogen, methyl or phenyl, Z is -CH = CH- or -CH 2 -CH 2 -, Y is oxygen or sulphur and R 3  is hydrogen or methyl and their acid addition salts are prepared by (1) reacting a compound II with a compound III in which X is an atom or group removable as an anion and is preferably halogen, tosyl or trialkylammonium, (2) cleaving a compound IV in which R is hydrogen or methyl and R 4  and R 5  are C 1-10  alkyl or aryl, or together are C 2-8  alkylene to form a Compound I (R=H or Me), (3) reacting a compound II with thiophene, furan, methyl thiophene or methyl furan and formaldehyde, (4) reacting a compound II with a compound VI in the presence of formic acid, (5) reducing a compound I in which Z is -CH=CH- to that in which Z is -OH 2 -CH 2 -, (6) reaction of a compound VII with an aldehyde CH 2  = CH-CO-R 1  to form a compound I (Z=-CH=CH-), (7) cleaving a protecting group &#34;Sch&#34; (which represents an alkyl aralkyl or ester group) in a compound I in which R is &#34;Sch&#34; to form a compound in which R is hydrogen or (8) methylation or acetylation of a compound I in which R is hydrogen. Compounds IV are produced by reacting a ketal XII in which R is hydrogen or methyl (prepared by demethylation using bromo cyanogen) with an acyl derivative XIV in which X is chlorine and reduction of the resulting amide with lithium aluminium hydride. Compounds VII may be analogously prepared starting from nor-thebane or nororipavine. Compounds I are analgesics and anti-tussives and exhibit morphine antagonism. They form with a carrier or excipient a pharmaceutical composition which may be administered orally or parenterally. The compositions may contain other analogous agents or sedatives, tranquillizers or hypnotics.
HNF-4 (hepatocyte nuclear factor 4) is a protein enriched in liver extracts that binds to sites required for the transcription of the transthyretin (TTR) and apolipoprotein CIII (apoCIII) genes (Costa et al., 1989; Costa et al., 1990; Leff et al., 1989). We have purified HNF-4 protein (54 kD) and isolated a cDNA clone encoding the protein. HNF-4 is a member of the steroid hormone receptor superfamily with an unusual amino acid in the conserved &#34;knuckle&#34; of the first zinc finger (DGCKG). This and the fact that HNF-4 does not bind significantly to estrogen, thyroid hormone or glucocorticoid response elements indicate that HNF-4 may represent a new subfamily. HNF-4 binds to its recognition site as a dimer and activates transcription in a sequence-specific fashion in nonhepatic (HeLa) cells. HNF-4 mRNA is present in kidney and intestine as well as liver but is absent in other tissues. DNA binding data suggest that HNF-4 could be identical to liver factor A1 (LF-A1), a factor previously shown to regulate the transcription of the alpha-1 antitrypsin, apolipoprotein A1 and pyruvate kinase genes.